title: The point-touch technique for botulinum toxin injection in adductor spasmodic dysphonia: quality of life assessment.
abstract: BACKGROUND
  Botulinum toxin injection under electromyographic guidance is the 'gold standard' for adductor spasmodic dysphonia treatment. The point-touch technique, an alternative injection method which relies on anatomical landmarks, is cheaper, quicker and more accessible, but has not yet gained widespread acceptance due to concerns about patient satisfaction.
  
  
  OBJECTIVE
  To assess swallowing and voice-related quality of life following point-touch botulinum toxin injection in adductor spasmodic dysphonia patients.
  
  
  METHODS
  Stanford University Voice and Swallowing Center.
  
  
  METHODS
  Prospective case series (evidence level four).
  
  
  METHODS
  Consecutive adductor spasmodic dysphonia patients with a stable botulinum toxin dose-response relationship were recruited prospectively. The Eating Assessment Tool and Voice-Related Quality of Life questionnaires were completed pre-treatment and at 10 and 30 per cent completion of the injection cycle, respectively.
  
  
  RESULTS
  Thirty-seven patients completed follow up. The mean total botulinum toxin dose was 0.88 units. Pre-treatment Voice-Related Quality of Life questionnaire results reflected the burden of disease. Post-treatment Eating Assessment Tool and Voice-Related Quality of Life questionnaire results were collected at 2.53 and 7.84 weeks, respectively; the former showed an increase in dysphagia, albeit statistically insignificant, while the latter showed significantly improved scores (both domain and total).
  
  
  CONCLUSIONS
  The point-touch technique is a viable alternative for botulinum toxin injection in the treatment of adductor spasmodic dysphonia.
authors.affiliation: Division of Laryngology, Department of Otolaryngology-Head and Neck Surgery, Stanford University School of Medicine, California, USA. Morzaria@yahoo.com
authors.forename: S
authors.initials: S
authors.lastname: Morzaria
authors.forename: E J
authors.initials: EJ
authors.lastname: Damrose
mesh_terms: D000328:Adult; D000368:Aged; D018726:Anti-Dyskinesia Agents / Q000008:administration & dosage*; D001905:Botulinum Toxins / Q000008:administration & dosage*; D003679:Deglutition / Q000187:drug effects / Q000502:physiology; D004305:Dose-Response Relationship, Drug; D055154:Dysphonia / Q000188:drug therapy* / Q000503:physiopathology; D004576:Electromyography; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular / Q000379:methods; D007821:Laryngeal Muscles; D007826:Laryngismus / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D017063:Outcome Assessment, Health Care / Q000706:statistics & numerical data; D011446:Prospective Studies; D011788:Quality of Life
chemical_list: D018726:Anti-Dyskinesia Agents; D001905:Botulinum Toxins